Patents by Inventor Kaushik Dave

Kaushik Dave has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STABILIZED RADIOLABELED ANTI-CD45 IMMUNOGLOBULIN COMPOSITIONS
    Publication number: 20220118122
    Abstract: Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition. The stabilized radiolabeled murine antibody binding the CD45 antigen expressed on various forms of lymphomas is useful as a radiotherapeutic and diagnostic agent in the treatment of human malignancies of hematopoietic origin, including lymphomas.
    Type: Application
    Filed: December 28, 2021
    Publication date: April 21, 2022
    Inventors: Kaushik DAVE, Shubh SHARMA
  • Stabilized radio-labeled anti-CD45 immunoglobulin compositions
    Patent number: 11241512
    Abstract: Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition. The stabilized radiolabeled murine antibody binding the CD45 antigen expressed on various forms of lymphomas is useful as a radio-therapeutic and diagnostic agent in the treatment of human malignancies of hematopoietic origin, including lymphomas.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: February 8, 2022
    Assignee: Actinium Pharmaceuticals, Inc.
    Inventors: Kaushik Dave, Shubh Sharma
  • STABILIZED RADIO-LABELED ANTI-CD45 IMMUNOGLOBULIN COMPOSITIONS
    Publication number: 20190321498
    Abstract: Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition. The stabilized radiolabeled murine antibody binding the CD45 antigen expressed on various forms of lymphomas is useful as a radio-therapeutic and diagnostic agent in the treatment of human malignancies of hematopoietic origin, including lymphomas.
    Type: Application
    Filed: June 28, 2019
    Publication date: October 24, 2019
    Applicant: Actinium Pharmaceuticals, Inc.
    Inventors: Kaushik DAVE, Shubh SHARMA
  • Stabilized radiolabeled anti-CD45 immunoglobulin compositions
    Patent number: 10420851
    Abstract: Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition. The stabilized radiolabeled murine antibody binding the CD45 antigen expressed on various forms of lymphomas is useful as a radiotherapeutic and diagnostic agent in the treatment of human malignancies of hematopoietic origin, including lymphomas.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: September 24, 2019
    Assignee: Actinium Pharmaceuticals, Inc.
    Inventors: Kaushik Dave, Shubh Sharma